Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.6%: Chuikyo
May 19, 2016
- Pricy Meds Again a Hot Topic at Chuikyo, MHLW Set to Launch Concrete Discussions
May 19, 2016
- AMED Initiates Project to Create Integrated Database for Clinical Genome Information
May 19, 2016
- Industry Opposes to Market Price Survey for Possible 2017 Revision; “No Reason to Conduct Survey if Sales Tax Hike Is Postponed”: FPMAJ Chairman
May 19, 2016
- Chuikyo OKs 16 APIs for Listing on May 25, Novartis’s Melanoma Combo Gets 45% Price Premium
May 18, 2016
- MHLW Advisory Panel to Discuss ASKA’s Hepatic Encephalopathy Treatment on May 30
May 18, 2016
- MHLW Advisory Panel to Discuss Sanofi’s PCSK9 Inhibitor on May 27
May 16, 2016
- Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
May 13, 2016
- MHLW Study Group Agrees MID-NET Database Should Be Made Available for Use in Post-Marketing Surveillance
May 13, 2016
- MHLW Panel Snubs 10-Valent Synflorix for Public Immunization Program
May 12, 2016
- Abe Tells Key Govt Panel to Compile FY2016 Economic, Fiscal Blueprint by May-End
May 12, 2016
- National Cancer Center to Strengthen Systems for Genome-Based Personalized Medicine and Rare Cancers: Pres. Nakagama
May 12, 2016
- MHLW Orders Teijin Pharma to Review Documents Submitted for Reexamination of 6 Products Including Bonalon
May 12, 2016
- Pharmacists Can Make Big Contribution to Health Finances by Reducing Drug Waste: MHLW Study Group Chief
May 10, 2016
- 18 of 24 Drug Firms in Kumamoto Have No Production Problem after Quakes: MHLW Update
May 10, 2016
- Bisphosphonates under Review for Risk of Osteonecrosis of External Auditory Canal
May 9, 2016
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
- Chuikyo Member Prods MHLW to Present Data on Savings through Generic Use
April 28, 2016
- Govt Achieves 8 Numerical Targets for FY2015 Plan to Promote R&D in Healthcare Field
April 28, 2016
- Chuikyo OKs 7 Drugs Subject to Cost-Effective Review; Re-Pricing to Be Conducted in 2018
April 27, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…